how do targeted treatments for idh1 and idh2 mutations work in acute myeloid leukemia (aml)?
Published 7 years ago • 521 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:53
treatment strategies for patients with idh1/2-mutated aml ineligible for intensive chemotherapy
-
2:57
targeting idh mutations for the treatment of aml
-
7:09
aml on the go: targeted therapy of idh1/idh2 mutated aml
-
3:23
the prognostic value of idh1 and idh2 in acute myeloid leukemia (aml)
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
1:14:18
joint iacrlrd/iach webinar: targeted diagnosis and therapy of npm1-mutated aml
-
4:10
explore idh mutations
-
8:08
how might olutasidenib long-term data impact treatment strategies in patients with idh1-mu r/r aml?
-
1:11
are idh mutations good minimal residual disease (mrd) markers in acute myeloid leukemia (aml)?
-
1:51
idh1/2 inhibitors for upfront aml therapy and transfusion independence
-
1:03
personalizing aml treatment by targeting mrd mutations
-
3:01
bay1436032: idh1 inhibition in idh1-mutated aml
-
2:08
the impact of idh mutations on the outcomes of patients with aml & inhibitors under investigation
-
1:32
idh inhibitors for aml and mds
-
2:51
aml: mutant idh1 inhibitor hms-101
-
2:46
the rapid progression of idh1/2 mutant enzyme inhibitors through clinical trials
-
1:32
idiome: ivosidenib in idh1 mutant mds
-
1:35
phase i study of ly3410738: a first-in-class idh1-r132 inhibitor
-
0:56
promising combinations being explored for idh1 & idh2-mutated aml
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
2:21
the future of aml treatment? progress in idh1/2 inhibitors for aml
-
1:19
the next steps for the idh2 inhibitor drug enasidenib